Psoriasis Clinical Trial
— MediDermInOfficial title:
Evaluation of the Therapeutic Efficacy of a Mindfulness-Based Stress Reduction (MBSR) Program as an Adjuvant Therapy in Patients With Moderate Pruritic Inflammatory Dermatosis (Psoriasis or Atopic Dermatitis)
Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world. Although the physiopathological mechanisms are not yet clearly defined, these inflammatory dermatoses involve an interaction between the immune system and the epidermal cells, severe skin inflammation and often very intense pruritus. The objectives of an effective management should be to treat lesions in order to reduce them, but also to reduce itching and allow the patients to accept and cope with their pathology, without neglecting an improvement in the "Dermatology Life Quality Index" (DLQI) and in the psychological state, sometimes depressive, of the patient. Itching is defined as "a feeling that needs to be scratched urgently" and can cause significant distress along with pain. It severely impacts the quality of life and the quality of sleep. Chronic itching is associated with increased stress, anxiety, and other mood disorders. In turn, stress and anxiety exacerbate the itching, leading to a vicious cycle of pruritus - scratching that affects patient behavior (excessive scratching) and worsens disease prognosis and quality of life. Much research over the past few decades has demonstrated the effect of mindfulness meditation on emotional and cognitive responsiveness, cognitive flexibility, rumination, self-compassion and mindfulness, but also on acute pain, anxiety, stress, depression, cardiovascular disease, eating disorders, cancer and cognitive loss with age. Several studies have shown the impact of mindfulness on brain function and immunity, with evidence for the association between mindfulness and changes in the levels of markers characteristic of immune system activity and inflammation, known to be increased in psoriasis or atopic dermatitis. The objective is to evaluate the effect of mental training in the regulation of stress and emotions through mindfulness meditation in patients with moderate, itchy atopic dermatitis or psoriasis, not treated with systemic agents (e.g.: biotherapies). This project is based on the premise that mental training in the regulation of stress and emotions through meditation would reduce the effects of the infernal itch-scratch cycle, alleviating pruritus, thus improving the well-being and mental health of patients while reducing their inflammatory skin lesions and limiting the appearance of new lesions.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | May 15, 2025 |
Est. primary completion date | September 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Days and older |
Eligibility | Inclusion Criteria: - Patient aged 18 years old or older - With health insurance coverage - Significant pruritus defined by a Visual Analogical Scale (VAS) pruritus = 4 - Patient with plaque psoriasis - Without joint involvement - Mild to moderate severity (PASI>10) - DLQI > 10 OR Patient with atopic dermatitis: - Mild to moderate severity (SCORAD>10) - DLQI > 10 - Diagnosis according to Hanifin and Raijka criteria - Patient in a stable psychological state - French langage spoken Exclusion Criteria : - Current systemic treatment or treatment discontinued within the last month - Psychiatric illnesses diagnosed according to the DSM-5 or ICD-10 international criteria of psychotic disorder, severe anxiety disorder, depressive disorder with a current depressive episode of severe intensity, bipolar disorder with a current depressive or manic episode - Taking psychotropic or neuroleptic treatments - Participation in another interventional research study or being in the exclusion period at the end of a previous study, if applicable - Patient under AME |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Saint-Louis | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pruritus assessed by Visual Analogue Scale (VAS) | VAS Pruritus scale is a scale going from 0 to 10. 0 corresponds to no pruritus et 10 to the maximum of prurit. | at 8 weeks | |
Secondary | Pruritus assessed by Visual Analogue Scale (VAS) | VAS Pruritus scale is a scale going from 0 to 10. 0 corresponds to no pruritus et 10 to the maximum of prurit. | at 16 weeks | |
Secondary | Pruritus assessed by 5-D Itch Scale 5-D (5-D IQ) | The 5-D itch scale is a multidimensional questionnaire. The scores of each of the domains are achieved separately and then summed together : total 5-D score can potentially range between 5 (no pruritus) and 25 (most severe pruritus). | at 8 weeks | |
Secondary | Pruritus assessed by 5-D Itch Scale 5-D (5-D IQ) | The 5-D itch scale is a multidimensional questionnaire. The scores of each of the domains are achieved separately and then summed together : total 5-D score can potentially range between 5 (no pruritus) and 25 (most severe pruritus). | at 16 weeks as compared to 8 weeks | |
Secondary | Number of dermatocorticoides tubes | at 8 weeks | ||
Secondary | Number of dermatocorticoides tubes | at 16 weeks as compared to 8 weeks | ||
Secondary | Number of scratches per day (including nights) | at 8 weeks | ||
Secondary | Number of scratches per day (including nights) | at 16 weeks as compared to 8 weeks | ||
Secondary | Psorasis Area and severity index (PASI Index) for psoriasis group | This score takes into account the affected skin surface, the degree of redness, the thickening of the skin and the scaling. Its ranges from 0 to 72.The higher the number, the more severe the psoriasis. | at 8 weeks | |
Secondary | Psorasis Area and severity index (PASI Index) for psoriasis group | This score takes into account the affected skin surface, the degree of redness, the thickening of the skin and the scaling. Its ranges from 0 to 72.The higher the number, the more severe the psoriasis. | at 16 weeks as compared to 8 weeks | |
Secondary | SCORAD Index for atopic dermatitis | The maximal score of the SCORAD Index is 103. | at 8 weeks | |
Secondary | SCORAD Index for atopic dermatitis | The maximal score of the SCORAD Index is 103. | at 16 weeks as compared to 8 weeks | |
Secondary | Stress evaluation assessed by Perceived Stress Scale | It is a 10 questions scale with 5 items per question. Its goes from 10 to 50. | at 8 weeks | |
Secondary | Stress evaluation assessed by Perceived Stress Scale | It is a 10 questions scale with 5 items per question. Its goes from 10 to 50. | at 16 weeks as compared to 8 weeks | |
Secondary | Quantification of inflammatory stress markers in saliva | Saliva stress markers will be alpha-amylase, cortisol, IL-6, IL-31 and TNF-alpha | at 8 weeks | |
Secondary | Quantification of inflammatory stress markers in saliva | Saliva stress markers will be alpha-amylase, cortisol, IL-6, IL-31 and TNF-alpha | at 16 weeks as compared to 8 weeks | |
Secondary | Quantification of inflammatory stress markers in serum | Serum stress markers will be CRP, cortisol, IL-6, IL-3, TNF-alpha and Adreno CorticoTropic Hormone | at 8 weeks | |
Secondary | Quantification of inflammatory stress markers in serum | Serum stress markers will be CRP, cortisol, IL-6, IL-31,TNF-alpha and Adreno CorticoTropic Hormone | at 16 weeks as compared to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |